Overview

SynOV1.1 Intratumoral Injection Study

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase I/IIa, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1, when administered as monotherapy and in combination with atezolizumab to participants with AFP positive HCC.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Beijing Syngentech Co., Ltd.

Treatments:

Atezolizumab